Abstract
Background: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer that has a poor prognosis. Currently, available treatments are cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy. However, an earlier population based study showed that in the Netherlands the majority of patients does not receive anti-cancer treatment. In 2015, Dutch Malignant Mesothelioma care was centralized in to two expert centers. Moreover, initiation of a phase-2 clinical trial in 2018 caused a boost in patients being referred.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
